• Home
  • News

Sichenzia Ross Ference Carmel LLP Represents EF Hutton LLC in $1.5 Million Underwritten Public Offering of NRx Pharmaceuticals

NRx Pharmaceuticals

Press Release – New York, NY –February 28, 2024 – Sichenzia Ross Ference Carmel LLP represents EF Hutton LLC in $1.5 million underwritten public offering of NRx Pharmaceuticals (the “Company”) (Nasdaq: NRXP), a clinical-stage biopharmaceutical company. The offering consisted of $0.30 per share, for aggregate gross proceeds of approximately $1,500,000, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 750,000 shares of common stock (or pre-funded warrants in lieu thereof). The offering is expected to close on February 28, 2024, subject to satisfaction of customary closing conditions. 

The Sichenzia Ross Ference Carmel LLP team was led by partners Ross Carmel, Avital Perlman, and associate Christian Lichtenberger.